Emerging Policy Issues in Synthetic Biology

Publié par OECD, le 04 juin 2014

168 pages

Résumé

Synthetic biology is at such an early stage of development that there is no uniform agreement as yet about what it actually is. To some, it represents a natural extension of genetic engineering, and therefore is "business as usual". For others, it is a way to bring mass manufacturing out from the decades of biotechnology research. Currently the discipline is limited by the ability to synthesise DNA cost-effectively but this is a technical barrier that it is anticipated will be overcome. Synthetic biology raises a number of policy issues around R&D funding, company investment, PPP arrangements and innovative financing, infrastructure requirements, education and training, intellectual property (IP), regulation, and public engagement. In preparation for the continuing development and greater use of synthetic biology, some countries have started to prepare synthetic biology technical roadmaps and a global roadmap for the medium term would be an extremely useful policy tool. Technical roadmaps could both identify likely future policy requirements, and be a useful vehicle in public engagement.

Changement climatique, eau et agriculture ; vers des systèmes résilients

Les politiques agricoles des pays de l'OCDE - Suivi et évaluation 2005

Global Forum on Transparency and Exchange of Information for Tax Purposes Peer Reviews : Australia 2013 - Global Forum on Transparency and Exchange of Information for Tax Purposes

Financing smes and entrepreneurs 2015

National accounts at a glance (édition 2015)

Des Politiques Du Marche Du Travail Novatrices

Startup América Latina - Promoviendo la innovacion en la region

Effective delivery of large infrastructure projects ; the case of the new international airport of Mexico City

Critiques